vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and Resolute Holdings Management, Inc. (RHLD). Click either name above to swap in a different company.
Resolute Holdings Management, Inc. is the larger business by last-quarter revenue ($117.7M vs $94.9M, roughly 1.2× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -1.5%, a 29.8% gap on every dollar of revenue. Resolute Holdings Management, Inc. produced more free cash flow last quarter ($189.2M vs $32.6M).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Resolute Mining Limited is an Australian mining corporation focused on mining operations in Africa. It is currently operating two gold mines: the Syama Gold Mine in Mali and the Mako Gold Mine in Senegal.
DVAX vs RHLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $117.7M |
| Net Profit | $26.9M | $-1.7M |
| Gross Margin | — | 55.7% |
| Operating Margin | 22.4% | 30.2% |
| Net Margin | 28.4% | -1.5% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | 53.0% | — |
| EPS (diluted) | $0.21 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $117.7M | ||
| Q3 25 | $94.9M | $120.9M | ||
| Q2 25 | $95.4M | $119.6M | ||
| Q1 25 | $68.2M | $103.9M | ||
| Q4 24 | $72.0M | — | ||
| Q3 24 | $80.6M | — | ||
| Q2 24 | $73.8M | — | ||
| Q1 24 | $50.8M | — |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $26.9M | $-231.0K | ||
| Q2 25 | $18.7M | $-611.0K | ||
| Q1 25 | $-96.1M | $-3.4M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $17.6M | — | ||
| Q2 24 | $11.4M | — | ||
| Q1 24 | $-8.7M | — |
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 59.0% | ||
| Q2 25 | — | 57.5% | ||
| Q1 25 | — | 52.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 30.2% | ||
| Q3 25 | 22.4% | 34.3% | ||
| Q2 25 | 15.1% | 34.0% | ||
| Q1 25 | -34.7% | 24.7% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 12.5% | — | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | -35.0% | — |
| Q4 25 | — | -1.5% | ||
| Q3 25 | 28.4% | -0.2% | ||
| Q2 25 | 19.6% | -0.5% | ||
| Q1 25 | -141.0% | -3.2% | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | 15.4% | — | ||
| Q1 24 | -17.2% | — |
| Q4 25 | — | $-0.20 | ||
| Q3 25 | $0.21 | $-0.03 | ||
| Q2 25 | $0.14 | $-0.07 | ||
| Q1 25 | $-0.77 | $-0.39 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.12 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $205.5M |
| Total DebtLower is stronger | — | $169.8M |
| Stockholders' EquityBook value | $534.1M | $6.5M |
| Total Assets | $946.5M | $333.4M |
| Debt / EquityLower = less leverage | — | 26.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $205.5M | ||
| Q3 25 | $160.2M | $148.0M | ||
| Q2 25 | $99.1M | $99.9M | ||
| Q1 25 | $51.7M | $71.0M | ||
| Q4 24 | $95.9M | — | ||
| Q3 24 | $119.3M | — | ||
| Q2 24 | $112.5M | — | ||
| Q1 24 | $132.0M | — |
| Q4 25 | — | $169.8M | ||
| Q3 25 | — | $173.4M | ||
| Q2 25 | — | $177.1M | ||
| Q1 25 | — | $180.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $6.5M | ||
| Q3 25 | $534.1M | $10.8M | ||
| Q2 25 | $494.2M | $9.6M | ||
| Q1 25 | $530.9M | $8.9M | ||
| Q4 24 | $596.8M | — | ||
| Q3 24 | $681.4M | — | ||
| Q2 24 | $642.8M | — | ||
| Q1 24 | $618.5M | — |
| Q4 25 | — | $333.4M | ||
| Q3 25 | $946.5M | $293.2M | ||
| Q2 25 | $918.4M | $253.3M | ||
| Q1 25 | $945.9M | $214.3M | ||
| Q4 24 | $986.3M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $986.6M | — |
| Q4 25 | — | 26.03× | ||
| Q3 25 | — | 16.01× | ||
| Q2 25 | — | 18.42× | ||
| Q1 25 | — | 20.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $196.1M |
| Free Cash FlowOCF − Capex | $32.6M | $189.2M |
| FCF MarginFCF / Revenue | 34.4% | 160.8% |
| Capex IntensityCapex / Revenue | 1.3% | 5.8% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $313.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $196.1M | ||
| Q3 25 | $33.8M | $59.6M | ||
| Q2 25 | $23.4M | $48.9M | ||
| Q1 25 | $-19.6M | $18.4M | ||
| Q4 24 | $53.0M | — | ||
| Q3 24 | $19.5M | — | ||
| Q2 24 | $10.7M | — | ||
| Q1 24 | $-16.7M | — |
| Q4 25 | — | $189.2M | ||
| Q3 25 | $32.6M | $58.6M | ||
| Q2 25 | $22.0M | $47.5M | ||
| Q1 25 | $-23.6M | $17.8M | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $-17.4M | — |
| Q4 25 | — | 160.8% | ||
| Q3 25 | 34.4% | 48.5% | ||
| Q2 25 | 23.0% | 39.7% | ||
| Q1 25 | -34.6% | 17.1% | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 13.5% | — | ||
| Q1 24 | -34.3% | — |
| Q4 25 | — | 5.8% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 1.5% | 1.2% | ||
| Q1 25 | 5.8% | 0.6% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RHLD
Segment breakdown not available.
